New guidance from the American College of Obstetricians and Gynecologists (ACOG) is drawing criticism from patient advocates and specialists who say it still falls short on the questions that matter most to people living with endometriosis: how to get diagnosed faster, when to refer patients to true specialists, and what the best treatment pathway should look like once the disease is suspected.
The story sits squarely in the health space. Endometriosis affects an estimated 1 in 10 women worldwide, according to the World Health Organization, yet diagnosis often takes years and treatment remains uneven. That disconnect helps explain why ACOG’s updated recommendations have become such a flashpoint.
What changed in the new guidance
ACOG said its updated clinical guidance is intended to shorten the time to diagnosis and improve access to care. One notable shift is that endometriosis no longer needs to be confirmed only through surgery and pathology before treatment begins. The new approach allows clinicians to evaluate symptoms and physical findings sooner, which in theory could help patients avoid years of dismissal and delay. ACOG outlined that goal in its announcement on the updated guidance here.
That is a meaningful acknowledgment of a problem many patients have described for years. Yale Medicine notes that diagnosis can take four to 11 years on average. During that time, patients may be told their pain is normal, cyclical, exaggerated or simply unexplained.
Why advocates and surgeons say it still is not enough
The frustration from advocates is less about whether the update contains some progress and more about what it leaves unsaid. Specialists argue the document does not clearly define who is qualified to treat complex endometriosis, when patients should be referred out, or how surgery should be handled when disease is discovered. For many in the field, that missing detail is not academic. It affects who gets effective treatment and who ends up cycling through incomplete care.
Endometriosis is a chronic inflammatory disease in which tissue similar to the lining of the uterus grows outside the uterus. It can affect the pelvic cavity, bowel, bladder and, in rare cases, more distant organs. The condition can cause severe pelvic pain, pain with menstruation, bowel or urinary symptoms, infertility and major quality-of-life disruptions. The WHO overview is available here.
What many specialists emphasize is that symptom management and disease removal are not the same thing. Hormonal suppression may help control pain for some patients, but it does not necessarily eliminate endometriosis lesions. Surgeons with deep experience in the disease often point to excision surgery as the gold-standard approach for carefully selected patients, especially in more advanced or complex cases. Advocates say the new guidance did not go far enough in distinguishing general gynecologic care from specialist-level endometriosis treatment.
The deeper problem: a shortage of expertise and funding
The dispute over the new guidelines also exposes a broader structural issue in women’s health: endometriosis remains underfunded, under-taught and frequently misunderstood. The National Institutes of Health tracks research funding across conditions, and advocates have long argued that endometriosis receives far less attention than its prevalence and burden would justify. NIH research information can be explored through the agency’s reporting tools here.
That lack of investment has consequences. If physicians receive limited training in identifying complex endometriosis on imaging, in recognizing when symptoms warrant specialist referral, or in performing advanced excision surgery, then even updated guidelines may not change outcomes very much on the ground. Patients can still encounter fragmented care, repeated procedures and years of uncertainty.
Why this story matters now
This latest debate lands at a time when women’s pain, diagnostic bias and gaps in reproductive health care are receiving greater public scrutiny. Recent years have brought more attention to how frequently patients report being dismissed in clinical settings, especially when symptoms are hard to see on routine testing. Endometriosis has become one of the clearest examples of that larger problem.
In that sense, the controversy over ACOG’s guidance is about more than one bulletin. It is about whether the U.S. medical system is prepared to treat chronic gynecologic pain as a serious, specialized medical issue rather than something patients are expected to simply tolerate. The updated guidance may represent progress, but to critics, progress without clarity risks reinforcing the same patchwork system patients have been navigating for years.
For now, the biggest unanswered question is whether future ACOG guidance will address referral standards, specialist definitions and treatment expectations more directly. Until then, advocates are likely to keep pressing for language that does more than validate pain. They want standards that measurably improve care.
Sources: Straight Arrow News; ACOG; World Health Organization; Yale Medicine; National Institutes of Health.
